reinforce

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohns diseasePress Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohns disease

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohns disease

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease New detailed data from the RELIEVE…

1 month ago
Longer-term data for Novartis Scemblix reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CMLLonger-term data for Novartis Scemblix reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

Longer-term data for Novartis Scemblix reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2%…

4 months ago